Literature DB >> 1960121

In-vitro susceptibility of Chlamydia pneumoniae (TWAR) to seven antibiotics.

M A Cooper1, D Baldwin, R S Matthews, J M Andrews, R Wise.   

Abstract

A modification of an immunofluorescence method previously used to study the in-vitro antimicrobial susceptibilities of Chlamydia trachomatis was used to investigate the activity of seven antimicrobials against a strain of C. pneumoniae. Our results differed from those obtained by other workers, so we modified our original method and repeated the study. Adding antimicrobial to pre-infected cells gave higher MICs and MLCs than when cells were infected in the presence of the antimicrobials, and this difference in methodology could account for the discrepancy between our results and those of others. Of the antimicrobials studied, clarithromycin and its 14-hydroxy metabolite were the most active agents; sparfloxacin was more active than ciprofloxacin, but no more active than more conventional antichlamydial agents.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1960121     DOI: 10.1093/jac/28.3.407

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  4 in total

1.  Chlamydia pneumoniae.

Authors:  T J Marrie
Journal:  Thorax       Date:  1993-01       Impact factor: 9.139

Review 2.  Antimicrobial susceptibility and therapy of infections caused by Chlamydia pneumoniae.

Authors:  M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

3.  In vitro activities of azithromycin, clarithromycin, and other antibiotics against Chlamydia pneumoniae.

Authors:  C C Kuo; L A Jackson; A Lee; J T Grayston
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

4.  In vitro susceptibilities of spotted fever group rickettsiae and Coxiella burnetti to clarithromycin.

Authors:  M Maurin; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.